Merck has begun the 8% reduction of its workforce—an initiative that the company revealed two weeks ago—with the dismissal of ...

Merck surged 3.35%, indicating a bullish trend as it challenged the $83.00 resistance mark. The stock's ascent is backed by ...

Even though Merck & Co., Inc.'s ( NYSE:MRK ) recent earnings release was robust, the market didn't seem to notice.

Facing patent expiration for its blockbuster Keytruda, Merck aims to streamline operations with significant job cuts and ...

Merck & Co., Inc. has kicked off two Phase 3 trials for its experimental PrEP therapy, MK-8527. **The trials, EXPrESSIVE-10 ...

On Tuesday, Merck & Co. Inc. (NYSE:MRK) released topline results from the Phase 3 KEYNOTE-905 trial (also known as EV-303) in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for ...

MRK trims its 2025 sales range but lifts the lower end of its EPS outlook. Keytruda, Animal Health and new drugs are expected ...

Merck KGaA is in the investment-grade market Tuesday, a day after holding investor calls, to help fund its $3.9 billion ...

Merck (MRK) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts ...

Merck & Co on Tuesday announced job and cost cuts that it said will save $3 billion a year, after it posted lower second-quarter results due to persistently weak demand for its Gardasil vaccine in ...

Merck & Co.’s COVID-19 pill was cleared by U.S. regulators Thursday, giving high-risk American patients a second at-home treatment just as the omicron variant is causing cases to surge around ...

Rival antiviral pills from Pfizer Inc. and Merck & Co. that demonstrated efficacy in trials of adults with COVID-19 who are at high risk of serious illness are now both in use.